发明公开
- 专利标题: NOVEL FGFR3 FUSION PRODUCT
- 专利标题(中): 新型FGFR3融合产品
-
申请号: EP13757006申请日: 2013-03-07
-
公开(公告)号: EP2824181A4公开(公告)日: 2015-07-15
- 发明人: SUZUKI ATSUSHI , ASAUMI MAKOTO , TSUNOYAMA KAZUHISA , NISHIMURA KOUICHI , MORINAKA AKIFUMI , YAMAUCHI TOMOHIRO , YOSHINO MASAYASU , YOSHIZAKI HIROAKI
- 申请人: ASTELLAS PHARMA INC
- 专利权人: ASTELLAS PHARMA INC
- 当前专利权人: ASTELLAS PHARMA INC
- 优先权: JP2012052147 2012-03-08; JP2012195451 2012-09-05; JP2012280325 2012-12-21
- 主分类号: C12N15/09
- IPC分类号: C12N15/09 ; A61K45/00 ; A61P35/00 ; C12Q1/68 ; G01N33/53
摘要:
[Problem] The present invention aims to elucidate a polynucleotide as a novel responsible gene for cancer and aims to thus provide a method for detecting the polynucleotide and a polypeptide encoded by the polynucleotide and a detection kit, a probe set, and a primer set for the detection. The present invention also aims to provide a pharmaceutical composition for treating cancer. [Means for Solution] The method detects a fusion gene composed of a portion of an FGFR3 gene and a portion of a TACC3 gene or a fusion protein encoded by the fusion gene. The primer set, the probe set, or the detection kit comprises a sense primer and a probe set designed from the portion encoding FGFR3 and an antisense primer and a probe set designed from the portion encoding TACC3. Since an inhibitor of the polypeptide exhibits antitumor effect, a pharmaceutical composition for treating cancer which is positive for either the fusion gene or the polypeptide is provided.
信息查询
IPC分类: